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age was 72.8 o 8.9 yrs, 65.1% were male and 78.7% had a history of hypertension. 
LTB was calculated as the proportion of patients receiving antihypertensive therapy 
who were not attaining guideline BP control targets. A hypothetical intervention to 
lower blood pressure to the normal range was applied to those individuals identiﬁed 
with LTB, to estimate the number of cardiovascular disease events which could 
be prevented. Logistic regression was used to ﬁnd the predictors of LTB and 
event rates were compared using Chi squared tests. RESULTS: Among the 2856 
Australian REACH participants, 70.1% (n  2002) had uncontrolled blood 
pressure (130/80 mmHg) and 88.3% (2522) had been taking anti-hypertensive 
medication. LTB was 70.7% (1784). The major univariate predictors of LTB 
were gender, age, diabetes, hypertension, carotid plaque, cholesterol, BMI and 
congestive heart failure. Assuming a hypothetical blood pressure intervention is applied 
to the LTB group resulting in controlled blood pressure (a130/80 mmHg), 8 cardiac 
events per 1000 people and 21 cardiovascular disease events including coronary 
heart disease intervention per 1000 people could be prevented. CONCLUSIONS: 
Improving BP control in patients receiving antihypertensive medication may prevent 
8 cardiac events per 1000 people and 21 CVD events per 1000 people within this 
study group. At a population level, this would represent a major cardiovascular event 
reduction strategy.
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RELATIONSHIP BETWEEN THE COST AND HOSPITAL QUALITY
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University of Michigan and STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: Inpatient surgery is a major component of overall health care 
spending. We examined variation in outlier payment across US hospitals and the 
extent to which variation is explained by quality of care. METHODS: We used the 
2006 Medicare Provider Analysis and Review (MEDPAR) ﬁle. We identiﬁed coronary 
artery bypass grafting (CABG).We ﬁrst describe the incidence of outlier payments for 
CABG, average outlier payment amount and their contribution to overall inpatient 
payments. We then explore how outlier payments vary according to patient charac-
teristics and across hospitals. Multiple logistic regression is used to examine to extent 
to which different factors serve as independent predictors of outlier payments. Stan-
dard errors are adjusted for the effect of clustering of outlier payments within hospi-
tals. In assessing variation in outlier payments across hospitals, we described the 
distribution of outlier payment prevalence (proportion of patients associated 
with outlier payments) by hospital. We, then assessed hospital variation using ﬁxed-
efects logistic regression models. RESULTS: The proportion of patients associated 
with outlier payment was 11%. Average outlier payments were considerable: $26,064. 
Outlier payment for CABG cost CMS approximately $480 million in 2006. Outlier 
payments were major contributors to the overall inpatient cost: 12.9%. Approxi-
mately 20% of hospitals had outlier rates below 5% for coronary artery bypass 
surgery, while 25% had outlier rates exceed 20%. Although, there were patient level 
risk factors that determine patient level otulier payment rates, this did not explain 
hospital level variation. Higher volume hospitals were less likely to have patients with 
outlier payments. CONCLUSIONS: Aiming to accelerate the quality improvements, 
payers are increasingly applying value-based purchasing strategies to surgical care. 
We showed that the variation in outlier payments across US hospitals is substantial 
for CABG and patient level risk factors can not explain hospital level variation. 
Hospital and surgical volume as a quality indicator is negatively related with 
outlier payments.
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VALVE IMPLANTATION USING MELODY VERSUS SURGICAL VALVE 
REPLACEMENT IN PATIENTS WITH RIGHT VENTRICULAR OUTFLOW 
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OBJECTIVES: To assess the cost of percutaneous pulmonary valve implantation 
(PPVI), a new procedure introduced in 2000 as a less invasive treatment for right             
ventricular outﬂow tract (RVOT) dysfunction, and the cost of surgical valve replace-      
ment in patients with right ventricular outﬂow tract dysfunction using a cohort simula-
tion model. METHODS: A cost analysis was performed from the perspective of the 
purchaser (the UK NHS). The cost of PPVI was estimated using data based on a total 
of 141 patients who had undergone PPVI from 2000 to 2008. The cost of surgical 
valve replacement in a similar group of patients was estimated using a cohort simula-
tion model populated with data drawn from the literature and expert opinion, given 
that PPVI has supplanted this procedure in the clinical setting analysed. The model is   
a cohort simulation model and assesses the cost of surgery using a hypothetical popula-
tion of 1000 individuals with right ventricular outﬂow tract dysfunction starting when        
their ﬁrst valved biological conduit was surgically placed and following them for a 
period of 25 years assuming that 1) PPVI is not available as an option, and 2) that 
PPVI is available for those eligible for it. RESULTS: The model resulted in an estimate 
of mean cost per patient of £5276 in the absence of PPVI and in an estimate of mean 
cost per patient of £7958 in the presence of PPVI over the 25 years period of analysis. 
CONCLUSIONS: PPVI although more costly than the surgical alternative, it appears 
to delay surgery thus having a signiﬁcant impact on the health and the quality of life 
of this patient population. More research is needed to quantify the magnitude of the 
impact on the quality of life and to assess the role of modelling generally in assessing 
costs and effects in medical devices.
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OBJECTIVES: The effect of hypertension on increased risk of cardiovascular disease 
events has been demonstrated through population based studies, and the predictive 
value of SBP has been repeatedly demonstrated in risk prediction models derived from 
such studies. A recent meta-analysis of evidence regarding SBP reduction by ARB 
antihypertensives has demonstrated a signiﬁcant difference in the SBP reduction 
observed in patients treated with valsartan, compared to those treated with losartan. 
An economic model has been constructed to evaluate the effect of this difference on 
the risk of a ﬁrst CVD event, and the resulting costs. METHODS: Inputs for the model 
are drawn from published sources and publically available datasets. CVD risk predic-
tion was performed using equations derived from the Framingham Offspring Study 
cohort. The model evaluated an untreated group, and groups treated with valsartan, 
and losartan. Each treatment group was stratiﬁed into those with mild hypertension 
or moderate hypertension. RESULTS: Basecase analyses represent outcomes over 20 
years from baseline moderate HTN classiﬁcation in a US population of age 18 and 
over. Valsartan was associated with a marginal cost of $1,983 vs. the untreated arm, 
and a marginal cost of $466 in comparison to losartan. These costs resulted in esti-
mates of $33,540 per event avoided vs. untreated and $37,484 vs. losartan. Incre-
mental costs per QALY were $7,067 vs. no treatment and $8,067 vs. losartan. 
CONCLUSIONS: Analysis results indicate that reduction in SBP from baseline is 
associated with small reductions in primary CVD rates, and overall CVD treatment 
costs. Valsartan performed better than losartan because it was associated with a 
greater decrease in SBP from baseline (according to meta-analysis results). Overall, the 
calculated cost effectiveness ratios for treatment with valsartan indicate that valsartan 
is likely to be cost-effective when compared to no treatment or treatment with losartan 
in control of SBP.
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OBJECTIVES: To investigate the efﬁciency of minimally-invasive Transcatheter Aortic 
Valve Implantation (TAVI) delivered through the transfemoral or transapical approach 
compared with open-heart conventional aortic valve replacement or medical manage-
ment alone in high risk patients with aortic stenosis in France. METHODS: A longi-
tudinal cohort model was developed to predict clinical and economic outcomes over 
three years in four cohorts of patients treated by either: transfemoral (TF) or transapi-
cal (TA) aortic valve implantation, surgical aortic valve replacement (AVR) or medical 
management (MED). Clinical outcomes included early perioperative complications (30 
days) and late events (stroke, MI, endocarditis, valve reoperation, pacemaker implan-
tation, hospitalization for acute heart failure, and death). In the absence of head-to-
head clinical trials, efﬁcacy data for the alternative approaches were extracted from 
various sources including clinical studies, registries, national health statistics and 
expert opinion. QALYs were assessed by mapping health utilities to NYHA class dis-
tribution. Direct medical costs were assessed by multiplying the number of resource 
items consumed with French unit costs (2008 values). RESULTS: In terms of predicted 
mean life years and QALYs per patient after 3 years, TAVI appears to be superior to 
the other approaches; 2.42 years or 1.76 QALYs for TF, 2.16 years or 1.61 QALYs 
for TA, versus 2.06 years or 1.50 QALYs for AVR, and 1.73 years or 0.98 QALYs 
for MED. Modeled average discounted (3%) cumulative direct medical costs per 
patient amount to a46,677 (TF), a45,468 (TA), a50,630 (AVR), and a78,208 (MED). 
These ﬁndings imply that both transcatheter approaches appear to be dominant versus 
conventional high-risk AVR as well as medical management. Probabilistic sensitivity 
analyses conﬁrmed the robustness of these model results. CONCLUSIONS: TAVI 
appears to be an economically promising technology. However, additional data from 
on-going clinical studies and registries need to be awaited to conﬁrm these preliminary 
results.
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COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN 
PATIENTS WITH ACUTE CORONARY SYNDROMES AND PLANNED PCI: 
RESULTS FROM THE TRITON-TIMI 38 TRIAL FROM THE GERMAN 
PERSPECTIVE
Mahoney EM1, Wang K1, McCollam PL2, Schmitt C3, Cohen DJ1
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OBJECTIVES: In patients with acute coronary syndromes (ACS) and planned PCI, 
the TRITON-TIMI 38 trial demonstrated that treatment with prasugrel compared 
with clopidogrel was associated with a reduced rate of cardiovascular death/MI/stroke 
and an increased risk of major bleeding. We evaluated the cost-effectiveness of treat-
ment with prasugrel vs. clopidogrel for the duration of the trial, from the perspective 
of the German health care system, based on data from TRITON-TIMI 38. METHODS: 
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Detailed resource utilization data were collected for all patients from 8 countries 
(U.S.,Australia,Canada,Germany,Italy,Spain,UK and France; n  3373 prasugrel, n  
3332 clopidogrel). Hospitalization costs were estimated from the perspective of the 
German health care system on the basis of diagnosis-related groups (DRGs) for 
Germany and in-hospital complications. Costs for cardiovascular medications were 
estimated using public price per tablet (clopidogrel  a2.68/day; prasugrel  a2.94/
day). Life expectancy (LE) was estimated based on in-trial cardiovascular and bleeding 
events, using statistical models developed from a similar population from the Saskatch-
ewan Health Database. Costs in added years of life were not included in the base case. 
The analysis was carried out for the overall cohort and the 10 mg. recommended 
population of patients with no history of stroke/TIA, age  75 and body wt. 60kg. 
RESULTS: Over a median 14.5 month follow-up period, average total costs were 
a15/patient (a20/patient for the 10 mg. recommended population) lower with prasu-
grel, due to a lower rate of rehospitalization involving PCI. Prasugrel was associated 
with LE gains of 0.102 years (0.129 for the 10 mg. recommended population), due 
primarily to the decreased rate of non-fatal MI. Compared to clopidogrel, prasugrel 
was thus an economically dominant treatment strategy. When compared to generic 
clopidogrel at a cost of  a1.80/day, there was an incremental net cost with prasugrel 
of a281/patient (a285/patient for the 10 mg. recommended population), and an ICER 
of a2743/life year gained (a2213/life year gained for the 10 mg. recommended popula-
tion). CONCLUSIONS: For ACS patients with planned PCI, prasugrel for up to 15 
months compared with current standard of care is an economically attractive treat-
ment strategy.
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THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT 
OF PULMONARY ARTERIAL HYPERTENSION IN IRELAND
Redmond S1, Bozkaya D2
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OBJECTIVES: Ambrisentan, a non-sulphonamide endothelin receptor antagonist 
(ERA) was recently licensed for the treatment of Pulmonary Arterial Hypertension 
(PAH). The study objective was to estimate the cost-effectiveness of ambrisentan from 
an Irish Healthcare perspective. METHODS: A discrete event simulation model devel-
oped by United BioSource Corporation was used to compare the cost-effectiveness of 
ambrisentan relative to two other ERAs (bosentan, sitaxentan) over a ﬁve year time 
horizon. The probability of clinical worsening and liver abnormality events were pre-
dicted from regression equations derived from the ambrisentan clinical trials data. 
These regression equations were also used to predict events for the comparator thera-
pies by calibrating them to reproduce treatment effects consistent with those reported 
in the literature. Costs and utilities were then assigned to these events and were dis-
counted at 3.5%. Costs were obtained from Irish speciﬁc and UK sources and were 
in 2007 prices. Utility values were derived from ambrisentan clinical trials. RESULTS: 
It was estimated that ambrisentan is cost saving with improved health outcomes 
compared to both bosentan and sitaxentan; ambrisentan dominated both bosentan 
(a195,788/QALY) and sitaxentan (a138,780/QALY). This result was driven by the 
higher incidence of liver abnormalities associated with bosentan and sitaxentan com-
pared to ambrisentan. When patients experienced liver abnormalities a proportion of 
them switched to prostacylin therapy, which was more expensive and associated with 
lower QALYs than ERA therapy. Probabilistic sensitivity analysis revealed that the 
likelihood of ambrisentan dominating bosentan and sitaxentan was 86% and 73%, 
respectively. CONCLUSIONS: Ambrisentan is a cost-effective alternative for the treat-
ment of PAH in Ireland. This is because it results in a lower incidence of liver abnor-
malities compared to existing ERAs.
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PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN 
PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING 
PERCUTANEOUS CORONARY INTERVENTION FROM THE 
PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE?  
A MODEL-BASED ANALYSIS
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OBJECTIVES: In patients with acute coronary syndromes (ACS) undergoing percu-
taneous coronary intervention (PCI), the TRITON-TIMI 38 trial (TTT) demonstrated 
that treatment with prasugrel vs. clopidogrel signiﬁcantly reduced rates of athero-
thrombotic events, though with increased risk of bleeding. We evaluated the long-term 
cost-effectiveness of this approach in patients free of stroke or TIA, from the perspec-
tive of the UK National Health Service. METHODS: A Markov model was developed 
based on risk equations for cardiovascular death, myocardial infarction (MI) or stroke, 
bleeding, and rehospitalisation, derived from TTT (N  13,608 patients). Hospital 
readmissions captured during the trial in all patients from 8 countries (N  6,705) 
were assigned to UK diagnosis related groups. After 12 months, common rehospitali-
sation costs were modelled to accrue over the life-time time horizon. RESULTS: 
During the ﬁrst year incremental drug cost of prasugrel (£162/patient) was partially 
offset by hospital cost savings (£14/patient) due principally to reduced revasculariza-
tion rates. Over the longer-term, prasugrel was associated with higher total costs 
resulting from rehospitalisations among survivors, of £169/patient, with life expec-
tancy gains of 0.06 years primarily due to reduced rate of MI, and 0.05 additional 
QALYs. Incremental cost per life year gained and per QALY gained were £2,606 and 
£3435 respectively. These results were consistent across subgroups, with incremental 
costs per QALY gained of £4494 in UA/NSTEMI, £2167 in STEMI, and £3461 in 
patients without any of three risk factors for bleeding (prior TIA/stroke, weight  
60kg, age q 75 years). Probabilistic sensitivity analysis indicated a 72% probability         
of prasugrel being cost-effective compared with branded clopidogrel at a willingness 
to pay of £20,000 per QALY. CONCLUSIONS: Prasugrel treatment to 1 year in 
ACS-PCI patients appears cost-effective compared with branded clopidogrel.
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PATIENTS ADMITTED TO THE ICU AFTER CARDIOPULMONARY 
RESUSCITATION: AN ANALYSIS OF OUTCOME, QUALITY OF LIFE  
AND COST-EFFECTIVENESS
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OBJECTIVES: Literature shows that patients admitted to the intensive care unit (ICU) 
after cardiopulmonary resuscitation (CPR) have a worse clinical and economic 
outcome in terms of increased length of stay (LOS) in the ICU and a high mortality. 
In this study we investigated survival, health-related quality of life (HRQOL), costs 
and cost-effectiveness of patients admitted to the ICU after CPR. METHODS: A pro-
spective observational cohort analysis was performed. In the period of March 3– 
November 3, 2008, all consecutive patients admitted to the ICU after CPR necessitating 
mechanical ventilation were screened for inclusion. All data concerning demography, 
comorbidity, severity of disease, organ failure, ICU and hospital LOS were analyzed. 
Data concerning costs were restricted to hospital-related costs and further to direct 
costs. HRQOL before admission and 3 months after ICU-discharge was assessed using 
standardized questionnaires (EuroQoL 5D, Short Form-36 scores). Statistical signiﬁ-
cance was attained at P  0.05. RESULTS: Out of 39 patients admitted because of 
CPR, 35 patients (66% males) with a mean age of 62 years (SD 14.6) and APACHE 
II-score of 26.9 (SD 9) were included. Mortality was 57%. The 15 patients that 
survived had an equal HRQOL before and after ICU-discharge concerning pain 
(P  0.6), general health (P  0.2), vitality (P  0.1), role-emotional (P  0.1) and 
mental health (P  0.9). HRQOL was diminished on physical functioning (P  0.01), 
role-physical (P  0.007) and social functioning (P  0.02). Costs per hospital survivor 
were a92,139, and a6,399/quality adjusted life year (QALY). A sensitivity-analysis 
conﬁrmed the cost-effectiveness of ICU treatment after CPR. CONCLUSIONS: 
Mortality after CPR was high and comparable with data from literature. After 
three months, HRQOL was only worse when looking at physical level. Treatment 
after CPR necessitating mechanical ventilation was found to be a cost-effective 
intervention.
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COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN AS ADJUNCTIVE 
THERAPY WITH FIBRINOLYSIS IN SPANISH PATIENTS WITH ST-
ELEVATION MYOCARDIAL INFARCTION (STEMI): RESULTS FROM 
EXTRACT-TIMI 25
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OBJECTIVES: ExTRACT-TIMI 25 is a prospective randomized trial of 20,479 
patients with 1,279 recruited in Spain. The use of enoxaparin as adjunctive therapy 
for ﬁbrinolysis in patients with ST-segment elevation myocardial infarction versus 
unfractionated heparin (UFH) resulted in a 17% relative risk reduction of death or 
non-fatal myocardial infarction (MI). Using results from the ExTRACT-TIMI 25 trial 
we conducted an economic evaluation to estimate the cost-effectiveness of enoxaparin 
in Spain. METHODS: Cost-effectiveness analysis was performed from the Spanish 
National Health Service perspective. Health resource data were obtained from the 
ExTRACT-TIMI 25 trial, coding according to Diagnostic Related Groups (DRGs). 
Medical direct costs data (procedures and drugs) were obtained from published 
Spanish literature. Survival and life expectancy were estimated from the Framingham 
Heart Study. Results are presented as incremental cost per life year gained (LYG) and 
cost per Quality Adjusted Life Years (QALY). To prove the robustness of the results 
we calculated 95% conﬁdence intervals for both costs and results. Long-term costs 
were discounted at 3% annually after the ﬁrst year. RESULTS: Considering short-term 
treatment results (30 days), enoxaparin achieved better results with more LYG than 
UFH but there was a not signiﬁcant difference in total costs. The incremental cost-
effectiveness ratio for enoxaparin obtained from the 30 days analysis was a977.5/
LYG. When long-term (lifelong) analysis was performed the cost obtained was of 
a2755.6/LYG and a3442.3/QALY. CONCLUSIONS: Considering the usual “willing-
ness to pay” cost-effectiveness threshold in Spain (a30,000 per LYG and per QALY) 
enoxaparin administered as adjunctive therapy for ﬁbrinolysis in ST-elevation myo-      
cardial infarction patients is a potentially cost-effective strategy compared with UFH 
in Spain.
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COST-EFFECTIVENESS OF AN EXERCISE TRAINING PROGRAM IN 
HEART FAILURE
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OBJECTIVES: Exercise training is an effective strategy to reduce combined clinical 
outcomes in heart failure (HF). Nonetheless, implementation of such programs 
has been restricted to university and specialized centers. Economic analysis of this 
